<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989258</url>
  </required_header>
  <id_info>
    <org_study_id>estPerMed 1, Breast</org_study_id>
    <nct_id>NCT03989258</nct_id>
  </id_info>
  <brief_title>Personalised Risk-based Breast Cancer Prevention and Screening</brief_title>
  <official_title>Implementation of a Model for Personalised Risk-Based Breast Cancer Prevention and Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Estonia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tartu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort study, applied research and T3 translational genomics to estimate the impact&#xD;
      of genetic risk for breast cancer detection in the screening program. The study group base&#xD;
      consists of 28 389 female participants, currently in the age-group 22-79, in the Biobank of&#xD;
      Estonian Genome Centre. The study is aimed to demonstrate the usability of personalised&#xD;
      approach for adjusting and stratifying screening recommendations, based on predicted genetic&#xD;
      risk estimates for breast cancer in the situation, where the genome data could be available&#xD;
      from all women who have given informed consent for that. The project includes both the&#xD;
      detection of moderate and high hereditary breast cancer risk carriers as well as high risk&#xD;
      polygenic risk-score (consisting several single nucleotide polymorphisms) carriers among&#xD;
      healthy individuals for application of personalised prevention and screening strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women in the population with genetically higher risk for breast cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of screen-detected breast cancers in different risk groups</measure>
    <time_frame>3-years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28389</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High monogenic breast cancer risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High polygenic breast cancer risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort StMG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard mammography screening in age 50-69</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mammography outside official screening</intervention_name>
    <description>Radiologic study</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1:&#xD;
&#xD;
          -  Available NGS (WGS or WES) data for detection of breast cancer moderate to high&#xD;
             genetic risk variants in BRCA1, BRCA2, TP53, STK11, PTEN, CDH1, ATM, PALB2, CHEK2,&#xD;
             NBN, NF1 genes;&#xD;
&#xD;
          -  Available genetic (WGS, genotyping) data for PRS calculation, participants in age&#xD;
             40-74 will be further selected;&#xD;
&#xD;
        Cohort 2:&#xD;
&#xD;
          -  Available genotyping data;&#xD;
&#xD;
          -  No available NGS data for BRCA1, BRCA2, TP53, STK11, PTEN, CDH1, ATM, PALB2, CHEK2,&#xD;
             NBN, NF1 genes;&#xD;
&#xD;
          -  Participants in the age group 40-74 with available genetic data for PRS calculation;&#xD;
&#xD;
        Cohort StMG:&#xD;
&#xD;
        â€¢ Female participants in Estonian Biobank in the age group 50-69 participating at least&#xD;
        once in the current Estonian population-based screening program during 2016-2020.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 1: breast cancer in the medical history; Cohort 2: breast cancer in the medical&#xD;
        history. Cohort StMG: none.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peeter Padrik, MD, PhD</last_name>
      <phone>+3727319800</phone>
      <email>peeter.padrik@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The North Estonia Medical Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vahur Valvere, MD,PhD</last_name>
      <phone>+3726172304</phone>
      <email>vahur.valvere@regionaalhaigla.ee</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tartu University Hospital</investigator_affiliation>
    <investigator_full_name>Peeter Padrik</investigator_full_name>
    <investigator_title>Director of the Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Screening</keyword>
  <keyword>Genetic risk</keyword>
  <keyword>Polygenic risk score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

